Histogen Provides Update on its Development Programs and Pipeline Focus
03 juin 2021 08h00 HE
|
Histogen Inc
Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates HST 003 Trial for Cartilage Regeneration in the Knee Remains On-Track with an Anticipated...
Histogen and Amerimmune Report Publication on Emricasan in COVID-19
19 mai 2021 08h00 HE
|
Histogen Inc
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Reports First Quarter 2021 Earnings and Provides Business Update
13 mai 2021 16h01 HE
|
Histogen Inc
Strengthened Balance Sheet with $20.8 Million of Gross Proceeds from Financing and Warrant Exercises Initiated Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients with Top-Line Data...
Histogen to Report Second Quarter 2021 Financial Results and Provide Business Update
28 avr. 2021 16h05 HE
|
Histogen Inc
SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen to Present at the 20th Annual Needham Virtual Healthcare Conference
30 mars 2021 08h00 HE
|
Histogen Inc
SAN DIEGO, March 30, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen Appoints Rochelle Fuhrmann to Board of Directors
25 mars 2021 16h05 HE
|
Histogen Inc
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients
16 mars 2021 08h00 HE
|
Histogen Inc
SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO) and Amerimmune LLC today announced dosing the first patient in a Phase 1 study of emricasan in mild symptomatic -COVID-19...
Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase 1/2 Trial for Knee Cartilage Regeneration
15 mars 2021 08h00 HE
|
Histogen Inc
Trial Initiation Anticipated in Second Quarter 2021 $2M Grant Awarded by the Department of Defense in September 2020 to Support Clinical Development SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) --...
Histogen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update
11 mars 2021 16h01 HE
|
Histogen Inc
Strengthened Balance Sheet with $25.3 Million of Gross Proceeds from Financings and Warrant Exercises Initiation of Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients Anticipated in the...
Histogen Strengthens Board of Directors with Appointment of Industry Leader Susan Windham-Bannister, Ph.D.
10 mars 2021 16h05 HE
|
Histogen Inc
SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...